Advances in IBD Precision Medicine With Therapeutic Drug Monitoring

Gain expert insights on current best practices for therapeutic drug monitoring in patients with IBD.

Marla Dubinsky, MD Bruce E. Sands, MD, MS Released: January 19, 2022

In this engaging, interactive, on-demand webcast, expert faculty review the rationale and current best practices for therapeutic drug monitoring (TDM) in patients with IBD. The data-driven discussion includes proactive and reactive TDM approaches for both TNF inhibitors and non-TNF inhibitor biologics.

Marla Dubinsky, MD Bruce E. Sands, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Released: February 16, 2022 Expired: February 15, 2023

Introduction and Presurvey

Why TDM for the Management of IBD?

Reactive vs Proactive TDM With Anti-TNFs

Early Induction and Dosing Calculators

Reactive and Proactive TDM With Non-TNFs

Two experts offer practical considerations for monitoring antidrug antibodies in patients with inflammatory bowel disease receiving anti-TNF therapy.

Marla Dubinsky, MD Bruce E. Sands, MD, MS Released: February 16, 2022

Should you screen every patient with inflammatory bowel disease for HLA-DQA1*05? Here’s our take.

Marla Dubinsky, MD Bruce E. Sands, MD, MS Released: March 2, 2022